Tempest Therapeutics
Tempest Therapeutics

Financials • Tempest Therapeutics

TPST

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year
12/2016
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2017
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2018
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2019
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2020
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2021
0
-27
-12
0%
L
36
L
-37
-
-27
-0
59
-27
0
0
-
-
12/2022
0
-34
-12
0%
L
18
L
-21
-
-33
-1
11
-33
0
0
-
-
12/2023
0
-29
-12
0%
L
27
L
-29
-
-30
-0
36
-30
0
0
-
-
12/2024
0
-42
-12
0%
L
19
L
-24
-
-38
-0
25
-39
0
0
-
-
12/2025
0
-26
-12
0%
L
7
L
-8
-
-30
0
4
-30
0
0
-
-

To see all financials—including updated, you must be Premium.